Table 2 Baseline characteristics of the included population
ID | Study groups | Number of participants | Age (Years), mean (SD) | Gender (male), Frequency | Type of migraine headache | Attacks per year Mean (SD) | Onset /Duration of attacks in h mean (SD) | Migraine with aura |
|---|---|---|---|---|---|---|---|---|
Friedman et al. 2020 [37] | Metoclopramide 10Â mg IV | 48 | 38 (11) | 14 | -- | -- | D: 99 (159) | 27 |
Bupivacaine 0.5% (6Â mL) | 51 | 39 (11) | 7 | -- | -- | D: 100 (137) | 26 | |
Yavuz et al. 2020 [31] | Metoclopramide 10Â mg IV | 50 | 38.1 (11.9) | 12 | -- | Median, IQR: 12 (6) | O: 4.4 (3.6) | 13 |
Dexketoprofen trometamol 50Â mg IV | 50 | 35.1 (11.3) | 15 | -- | Median, IQR: 12 (5) | O: 5.6 (7.3) | 15 | |
Khazaei et al. 2019 [28] | Metoclopramide 10Â mg IV | 32 | Total; Migraine with aura: 37.81 (9.27) Migraine without aura: 36.56 (10.1) | -- | -- | -- | -- | 7 |
Dexamethasone 8Â mg IV | 32 | -- | -- | -- | -- | 3 | ||
Chlorpromazine 25Â mg IV | 32 | -- | -- | -- | -- | 11 | ||
Ketorolac 30Â mg IV | 32 | -- | -- | -- | -- | 6 | ||
DoÄŸan et al. 2019 [35] | Metoclopramide 10Â mg IV | 74 | 33.67 (13.33) | 24 | -- | 14.33 (12.59) | O: 7 (8.15) | 23 |
Normal saline 100Â ml | 74 | 33 (13.33) | 28 | -- | 19 (17.04) | O: 5.67 (4.44) | 16 | |
Amiri et al. 2017 [32] | Metoclopramide 10 mg IV | 73 | Total; Mean: 33.5 | Total; Males = 47 | -- | -- | -- | -- |
Granisetrone 2Â mg IV | 75 | -- | -- | -- | -- | |||
Friedman et al. 2014 [38] | Metoclopramide 10Â mg IV | 110 | 34.67 (13.33) | 18 | -- | -- | D: 88 (106.67) | 52 |
Ketorolac 30Â mg IV | 110 | 34.33 (14.07) | 17 | -- | -- | D: 86 (102.22) | 53 | |
Valproate 1 gm IV | 110 | 33 (11.85) | 19 | -- | -- | D: 72 (71.11) | 53 | |
Talabi et al. 2013 [30] | Metoclopramide 20Â mg IV | 62 | 34.9 (9) | 39 | -- | -- | -- | -- |
Sumatriptan 6Â mg SC | 62 | 26.8 (4) | 38 | -- | -- | -- | -- | |
Salazar-Zúñiga et al. 2006 [29] | Metoclopramide 10 mg IV | 60 | Range from 18–65 | Total; Males: 9 | -- | -- | -- | -- |
Sumatriptan 6Â mg SC | 60 | -- | -- | -- | -- | |||
Cicek et al. 2004 [34] | Metoclopramide 10 mg IV + Placebo IM | 50 | Total; 38.8 (11.1) | Total; Males: 23 | -- | -- | -- | -- |
Placebo IV + Placebo IM | 48 | -- | -- | -- | ||||
Pethidine 50 mg IM + Placebo IV | 49 | -- | -- | -- | ||||
Cete et al. 2005 [19] | Metoclopramide 10 mg IV + 100 ml normal saline | 37 | 40 (13) | 4 | -- | -- | -- | 5 |
Normal saline 100Â ml IV | 40 | 10 (11) | 5 | -- | -- | -- | 8 | |
MgSO4 2 mg + 100 ml normal saline | 36 | 40 (12) | 9 | -- | -- | -- | 7 | |
Jones et al. 1996 [21] | Metoclopramide 10Â mg IM | 29 | Total; 32.1 (2.1) | Total; Males: 21 | -- | -- | -- | -- |
Normal saline 2Â ml IM | 29 | -- | -- | -- | -- | |||
Prochlorperazine 10Â mg IM | 28 | -- | -- | -- | -- | |||
Coppola et al. 1995 [15] | Metoclopramide 10Â mg IV | 24 | -- | -- | -- | -- | -- | -- |
Normal saline 2Â ml IV | 24 | -- | -- | -- | -- | -- | -- | |
Prochlorperazine 10Â mg IV | 22 | -- | -- | -- | -- | -- | -- | |
Cameron et al. 1995 [33] | Metoclopramide 0.1 mg/kg IV | 44 | 31.6 Range: 19–54 | 9 | -- | -- | D: 47.2 Range: 1 – 456 | 8 |
Chlorpromazine 0.1 mg/kg IV | 47 | 32.6 (66.46) Range: 17–55 | 9 | -- | -- | D: 38.9 Range:1.5 – 576 | 7 | |
Ellis et al. 1993 [36] | Metoclopramide 10 mg IV + Placebo oral | 10 | At least 18 years old | -- | -- | -- | -- | -- |
Placebo oral and IV | 10 | -- | -- | -- | -- | -- | ||
Ibuprofen 600 mg oral + Placebo IV | 10 | -- | -- | -- | -- | -- | ||
Tek et al. 1990 [18] | Metoclopramide 10 mg IV | 24 | Range: 18–60 years old | -- | 7 had classic migraine 39 had common migraine 4 not differentiated | -- | -- | -- |
Normal saline 2Â ml | 26 | -- | -- | -- | -- | |||
Tfelt-Hansen et al. 1980 [22] | Metoclopramide 10 mg IM + Placebo suppository | 49 | Total; 43.25 (14) Range: 18–74 | Total; Males: 17 | Classical and common migraine | Median: 1.5 per month | Total; Attacks <4 h = 18 (12%) Attacks 4–24 h = 95 (63%) Attacks ≥25 h = 37 (25%) | -- |
Placebo IM + Placebo suppository | 51 | -- | ||||||
Metoclopramide 20 mg suppository + Placebo IM | 50 | -- |